JP2011502956A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502956A5
JP2011502956A5 JP2010504681A JP2010504681A JP2011502956A5 JP 2011502956 A5 JP2011502956 A5 JP 2011502956A5 JP 2010504681 A JP2010504681 A JP 2010504681A JP 2010504681 A JP2010504681 A JP 2010504681A JP 2011502956 A5 JP2011502956 A5 JP 2011502956A5
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
methyl
compound
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504681A
Other languages
English (en)
Japanese (ja)
Other versions
JP5693951B2 (ja
JP2011502956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/054975 external-priority patent/WO2008129070A1/en
Publication of JP2011502956A publication Critical patent/JP2011502956A/ja
Publication of JP2011502956A5 publication Critical patent/JP2011502956A5/ja
Application granted granted Critical
Publication of JP5693951B2 publication Critical patent/JP5693951B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504681A 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤 Expired - Fee Related JP5693951B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2007/003602 2007-04-24
EP2007003602 2007-04-24
PCT/EP2008/054975 WO2008129070A1 (en) 2007-04-24 2008-04-24 Inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2011502956A JP2011502956A (ja) 2011-01-27
JP2011502956A5 true JP2011502956A5 (enExample) 2011-06-16
JP5693951B2 JP5693951B2 (ja) 2015-04-01

Family

ID=39588050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504681A Expired - Fee Related JP5693951B2 (ja) 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤

Country Status (4)

Country Link
US (1) US8436007B2 (enExample)
JP (1) JP5693951B2 (enExample)
ES (1) ES2539518T3 (enExample)
WO (1) WO2008129070A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5693951B2 (ja) 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
WO2008129080A1 (en) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
US8389521B2 (en) * 2007-04-24 2013-03-05 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP2012532148A (ja) * 2009-07-08 2012-12-13 喬本生医股▲ふん▼有限公司 リュウガン種子抽出物の製造方法及びその応用
JP2013107824A (ja) * 2010-03-17 2013-06-06 Dainippon Sumitomo Pharma Co Ltd 新規単環ピリミジン誘導体
EA026917B1 (ru) * 2010-03-22 2017-05-31 Лид Дискавери Сентр Гмбх Фармацевтически активные производные двузамещенного триазина
WO2012066065A1 (en) * 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CN103562184B (zh) * 2011-03-02 2016-04-27 利德探索中心有限公司 药学活性的二取代的吡啶衍生物
KR20140019381A (ko) * 2011-04-19 2014-02-14 바이엘 인텔렉쳐 프로퍼티 게엠베하 치환된 4-아릴-n-페닐-1,3,5-트리아진-2-아민
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
WO2013037894A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
US9108926B2 (en) * 2011-09-16 2015-08-18 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
CA2888383A1 (en) * 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
CN104854091B (zh) * 2012-10-18 2018-04-03 拜耳药业股份公司 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
JP2015536311A (ja) * 2012-10-18 2015-12-21 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含有する4−(オルト)−フルオロフェニル−5−フルオロピリミジン−2−イルアミン
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
CN104918918B (zh) * 2012-11-15 2017-10-24 拜耳药业股份公司 含磺亚胺基团的4‑(邻)‑氟苯基‑5‑氟嘧啶‑2‑基胺
JP6263193B2 (ja) 2012-11-15 2018-01-17 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン基を含んでいる5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体
JP6371385B2 (ja) 2013-07-04 2018-08-08 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン置換5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体およびそのcdk9キナーゼ阻害薬としての使用
JP2017508757A (ja) 2014-03-13 2017-03-30 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含有する5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体
EP3126338B1 (en) * 2014-04-01 2019-09-04 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
EP3129387B1 (en) 2014-04-11 2019-06-26 Bayer Pharma Aktiengesellschaft Novel macrocyclic compounds
CN107207475A (zh) 2014-10-16 2017-09-26 拜耳医药股份有限公司 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物
WO2016059086A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
JP2018509439A (ja) 2015-03-24 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト 多発性骨髄腫を治療するための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用
JP2018509440A (ja) 2015-03-24 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト リンパ腫の治療のための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用
HUE043440T2 (hu) 2015-06-29 2019-08-28 Astrazeneca Ab Policiklusos amidszármazékok mint CDK9 inhibitorok
ES2786552T3 (es) 2015-09-29 2020-10-13 Bayer Pharma AG Compuestos de sulfondiimina macrocíclicos nuevos
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
KR102764122B1 (ko) 2018-02-13 2025-02-05 바이엘 악티엔게젤샤프트 미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도
CA3172328A1 (en) * 2020-03-27 2021-09-30 Haruhisa Inoue Nerve cell degeneration inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319568D0 (en) * 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
GB2361236B (en) * 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
WO2003066601A1 (en) * 2002-02-08 2003-08-14 Smithkline Beecham Corporation Pyrimidine compounds
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
EP1648875A1 (en) * 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
ES2325035T3 (es) * 2004-12-21 2009-08-24 Smithkline Beecham Corporation Inhibidores de quinasa erbb de 2-pirimidinil pirazolopiridina.
US20090221581A1 (en) * 2005-05-25 2009-09-03 Philipp Wabnitz Methods of treating pain
US8507511B2 (en) * 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP5693951B2 (ja) 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
US8389521B2 (en) * 2007-04-24 2013-03-05 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases

Similar Documents

Publication Publication Date Title
JP2011502956A5 (enExample)
JP2010525023A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2016500661A5 (enExample)
JP2013510124A5 (enExample)
JP2020506951A5 (enExample)
JP2015535277A5 (enExample)
JP2011137006A5 (enExample)
JP2014520863A5 (enExample)
JP2014506599A5 (enExample)
JP2016520131A5 (enExample)
JP2017502940A5 (enExample)
JP2009533410A5 (enExample)
JP2013522292A5 (enExample)
JP2014520898A5 (enExample)
JP2016525075A5 (enExample)
JP2014508811A5 (enExample)
JP2013537203A5 (enExample)
JP2015504067A5 (enExample)
JP2016506958A5 (enExample)
JP2014523432A5 (enExample)
JP2006522118A5 (enExample)
JP2014518543A5 (enExample)
JP2013544860A5 (enExample)
JP2013508288A5 (enExample)